MetaVia Inc. (MTVA)Healthcare | Biotechnology | Cambridge, United States | NasdaqCM
1.70 USD
+0.04
(2.410%)
⇧
(Aug. 28, 2026, 4 p.m.
EDT)
After hours: 1.71 +0.01 (0.588%) ⇧ (Aug. 28, 2026, 7:06 p.m. EDT) |
Hot Take ↕ | Aug. 22, 2026, 5:33 a.m. EDT
The immediate outlook remains deeply bearish due to a catastrophic multi-year price collapse. Despite a recent spike driven by conference catalysts, the underlying asset has suffered nine consecutive years of negative annual returns, erasing nearly 100% of its value over the last decade. This relentless downward trajectory suggests the market has permanently reassessed the business quality, rendering any short-term momentum recovery highly suspect without a fundamental turnaround. The company is burning through cash with significant negative free cash flow and negative returns on both assets and equity, while offering no dividend support. While analysts project a massive recovery, the historical data indicates a structural deterioration rather than a temporary dip, making this a high-risk speculative play rather than a viable investment. |
| Model | MAE |
|---|---|
| AutoARIMA ✓ | 0.068156 |
| AutoETS | 0.068157 |
| AutoTheta | 0.068212 |
| MSTL | 0.075197 |
Forecast horizon: 45 days | Selected: AutoARIMA
| Forecast Reliability | |
|---|---|
| Score | 31% |
| H-stat | 0.22 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.002 |
| Excess Kurtosis | 0.58 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 2.595 |
| Market Cap | 11,199,772 |
| Beta | 0.90 |
| Website | https://www.metaviatx.com |
| Attribute | Value |
|---|---|
| 52 Week Change | -0.76309407 |
| Address1 | 545 Concord Avenue |
| Address2 | Suite 210 |
| All Time High | 1,424,940.0 |
| All Time Low | 0.966 |
| Ask | 2.15 |
| Ask Size | 2 |
| Average Analyst Rating | 1.0 - Strong Buy |
| Average Daily Volume10 Day | 74,660 |
| Average Daily Volume3 Month | 615,611 |
| Average Volume | 615,611 |
| Average Volume10Days | 74,660 |
| Beta | 0.903 |
| Bid | 1.22 |
| Bid Size | 2 |
| Book Value | 1.037 |
| City | Cambridge |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 1.7 |
| Current Ratio | 2.059 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,786,665,600 |
| Day High | 1.7315 |
| Day Low | 1.67 |
| Debt To Equity | 2.595 |
| Display Name | MetaVia |
| Dividend Date | 1,577,750,400 |
| Earnings Timestamp End | 1,755,520,200 |
| Earnings Timestamp Start | 1,755,001,800 |
| Ebitda | -14,912,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | 0.084 |
| Enterprise Value | -1,259,228 |
| Eps Trailing Twelve Months | -2.45 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 1.5546 |
| Fifty Day Average Change | 0.14540005 |
| Fifty Day Average Change Percent | 0.09352891 |
| Fifty Two Week Change Percent | -76.30941 |
| Fifty Two Week High | 19.03 |
| Fifty Two Week High Change | -17.33 |
| Fifty Two Week High Change Percent | -0.91066736 |
| Fifty Two Week Low | 0.966 |
| Fifty Two Week Low Change | 0.734 |
| Fifty Two Week Low Change Percent | 0.7598344 |
| Fifty Two Week Range | 0.966 - 19.03 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,470,403,800,000 |
| Float Shares | 4,805,163 |
| Free Cashflow | -11,086,875 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 8 |
| Fullday Change | 0.0400001 |
| Fullday Change Percent | 2.40964 |
| Fullday Price | 1.71 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.0 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.2861 |
| Held Percent Institutions | 0.13866 |
| Implied Shares Outstanding | 6,588,101 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,764,892,800 |
| Last Split Factor | 1:11 |
| Long Business Summary | MetaVia Inc., a clinical-stage biotechnology company, focuses on developing novel pharmaceuticals to treat cardiometabolic diseases. The company develops DA-1241, a novel G-Protein-Coupled Receptor 119 agonist with development optionality as a standalone and/or combination therapy that is in Phase 2a clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis, as well as completed Phase 1 clinical trial for the treatment of type 2 diabetes mellitus; and DA-1726, a novel oxyntomodulin analogue functioning as a GLP-1 receptor and glucagon receptor dual agonist, which is in Phase 1 trial for the treatment of obesity. Its therapeutic programs include ANA001, a proprietary oral niclosamide formulation for the treatment of patients with moderate COVID-19; NB-01 for the treatment of painful diabetic neuropathy; NB-02 for the treatment of cognitive impairment; and Gemcabene for the treatment of dyslipidemia. The company has a license agreement with Pfizer Inc. for the research, development, manufacture, and commercialization of Gemcabene; and Dong-A ST, a sole manufacturer for the production of DA-1241 and DA-1726. The company was formerly known as NeuroBo Pharmaceuticals, Inc. and changed its name to MetaVia Inc. in November 2024. MetaVia Inc. is headquartered in Cambridge, Massachusetts. |
| Long Name | MetaVia Inc. |
| Market | us_market |
| Market Cap | 11,199,772 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_630763379 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | -14,446,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 10,936,247 |
| Number Of Analyst Opinions | 3 |
| Open | 1.6901 |
| Operating Cashflow | -15,835,000 |
| Operating Margins | 0.0 |
| Payout Ratio | 0.0 |
| Phone | 857 702 9600 |
| Post Market Change | 0.00999999 |
| Post Market Change Percent | 0.5882347 |
| Post Market Price | 1.71 |
| Post Market Time | 1,787,958,416 |
| Previous Close | 1.66 |
| Price Hint | 4 |
| Price To Book | 1.6393445 |
| Profit Margins | 0.0 |
| Quick Ratio | 1.991 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.0 |
| Region | US |
| Regular Market Change | 0.0400001 |
| Regular Market Change Percent | 2.40964 |
| Regular Market Day High | 1.7315 |
| Regular Market Day Low | 1.67 |
| Regular Market Day Range | 1.67 - 1.7315 |
| Regular Market Open | 1.6901 |
| Regular Market Previous Close | 1.66 |
| Regular Market Price | 1.7 |
| Regular Market Time | 1,787,947,201 |
| Regular Market Volume | 36,567 |
| Return On Assets | -0.58821 |
| Return On Equity | -1.7567799 |
| Sand P52 Week Change | 0.20504117 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 6,588,101 |
| Shares Percent Shares Out | 0.0321 |
| Shares Short | 211,343 |
| Shares Short Previous Month Date | 1,784,073,600 |
| Shares Short Prior Month | 344,566 |
| Short Name | MetaVia Inc. |
| Short Percent Of Float | 0.043899998 |
| Short Ratio | 1.89 |
| Source Interval | 15 |
| State | MA |
| Symbol | MTVA |
| Target High Price | 30.0 |
| Target Low Price | 8.0 |
| Target Mean Price | 19.33333 |
| Target Median Price | 20.0 |
| Total Cash | 12,636,000 |
| Total Cash Per Share | 1.918 |
| Total Debt | 177,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -2.45 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 3.21935 |
| Two Hundred Day Average Change | -1.51935 |
| Two Hundred Day Average Change Percent | -0.4719431 |
| Type Disp | Equity |
| Volume | 36,567 |
| Website | https://www.metaviatx.com |
| Zip | 2,138 |